Compass Pathways

announced in February 2026 that its second Phase 3 trial (COMP006) of COMP360 synthetic psilocybin met its primary endpoint in treatment-resistant depression, building on its first positive Phase 3 result.

Country: United Kingdom
Ticker: CMPS

psilocybin eu

Coverage

	CN	EU	US
therapeutics-platforms	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Funding	$150 million financing in February 2026 and $200 million in warrant exercises reported in 2026, with total funding approximately $948.7 million reported as of October 2024	ir.compasspathways.com · sec.gov
Capacity	The company is working on the scalability and commercial viability of manufacturing methods and investigating the addition of commercial manufacturing capacity in the U.S.	content.edgar-online.com
Certification	Breakthrough Therapy designation from the U.S. FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK for COMP360 in treatment-resistant depression	ir.compasspathways.com · sec.gov
Regulatory approval	Rolling New Drug Application (NDA) submission and review with the U.S. FDA is underway, with final submission expected in Q4 2026; COMP360 has not yet received marketing approval	ir.compasspathways.com · sec.gov
Production site	The company is developing manufacturing processes for COMP360 but no specific production sites are explicitly named as active for commercial production medium confidence	content.edgar-online.com
Headcount	156 employees as of December 31, 2025	marketscreener.com
Revenue	The company reports net income/loss rather than revenue; reported a net income of $91.2 million for Q1 2026 and a net loss of $162.6 million for the first half of 2026	s204.q4cdn.com · sec.gov

Independent sources: content.edgar-online.com · marketscreener.com · s204.q4cdn.com · sec.gov

Technologies

Name	Cluster	Risk
Psychedelic medicine & neuropsychiatric biologics	therapeutics-platforms	High	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.